Novo Nordisk today announced the broad commercial availability of the Wegovy® (semaglutide) pill across the United States, marking a significant milestone in obesity medicine. This launch introduces the first and only oral GLP-1 receptor agonist approved for weight management in adults, offering a new therapeutic avenue for the estimated 100 million Americans living with obesity.
The FDA approved the oral formulation on December 22, 2025. The pill is indicated as an adjunct to a reduced-calorie diet and increased physical activity for adults with obesity or those with overweight and have weight-related comorbidities.
The arrival of an oral option is expected to significantly expand patient access to GLP-1 therapies, building on the widespread demand for the original injectable version of Wegovy®, which has been prescribed to millions since 2021.
Clinical Trial Efficacy: The OASIS 4 Results
The approval of oral Wegovy® was supported by data from the Phase 3 OASIS 4 clinical trial, which demonstrated weight loss magnitudes previously unseen in oral GLP-1 candidates.
According to Novo Nordisk, trial participants taking the 25 mg once-daily pill achieved significant weight reduction over 64 weeks compared to placebo. The results were analyzed in two ways:
- Ideal Adherence Scenario: In an analysis assuming all patients stayed on treatment and adhered strictly to the regimen, those taking the Wegovy® pill achieved an average weight loss of approximately 17% (16.6%), compared to about 3% for placebo.
- Real-World Scenario: When assessing efficacy regardless of whether patients stayed on treatment, the average weight loss was approximately 14% (13.6%) for the Wegovy® group, compared to about 2% for placebo.
Baseline body weights for participants were approximately 235 lbs for the treatment group and 231 lbs for the placebo group.
The safety profile of the oral pill in OASIS 4 was consistent with previous trials of the injectable version. Common adverse reactions included gastrointestinal issues such as nausea, diarrhea, and vomiting.
Pricing, Doses, and Availability
The Wegovy® pill is available in four distinct strengths to allow for dose escalation: 1.5 mg (starter dose), 4 mg, 9 mg, and 25 mg.
To ensure broad access, Novo Nordisk has established multiple purchasing channels. The medication is available through traditional US pharmacies like CVS and Costco, select telehealth providers including Ro, LifeMD, and Weight Watchers, as well as NovoCare® Pharmacy and GoodRx.
Novo Nordisk has released a tiered pricing structure to aid affordability:
- Commercially Insured Patients: Eligible patients with commercial insurance may pay as little as $25 per month utilizing the Wegovy® savings offer (subject to a maximum monthly savings of $100).
- Self-Pay Patients:
- The starting 1.5 mg dose is available for approximately $149 per month (roughly $5/day).
- The 4 mg dose is priced at $149 per month through April 15, 2026, after which it will increase to $199 per month.
- The highest maintenance doses will be available for approximately $299 per month.
The oral Wegovy® pill is currently approved only for use within the United States.
Last Modified:
